Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

Applied Therapeutics (APLT) EPS (Basic) (2023 - 2025)

Historic EPS (Basic) for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$0.13.

  • Applied Therapeutics' EPS (Basic) rose 7291.67% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.1, marking a year-over-year increase of 9315.07%. This contributed to the annual value of -$0.72 for FY2024, which is 4914.44% up from last year.
  • Latest data reveals that Applied Therapeutics reported EPS (Basic) of -$0.13 as of Q3 2025, which was up 7291.67% from -$0.15 recorded in Q2 2025.
  • Applied Therapeutics' 5-year EPS (Basic) high stood at $0.02 for Q2 2024, and its period low was -$0.67 during Q1 2024.
  • Its 3-year average for EPS (Basic) is -$0.29, with a median of -$0.23 in 2024.
  • In the last 5 years, Applied Therapeutics' EPS (Basic) soared by 10540.54% in 2024 and then plummeted by 85000.0% in 2025.
  • Over the past 3 years, Applied Therapeutics' EPS (Basic) (Quarter) stood at -$0.33 in 2023, then soared by 30.37% to -$0.23 in 2024, then surged by 43.42% to -$0.13 in 2025.
  • Its EPS (Basic) was -$0.13 in Q3 2025, compared to -$0.15 in Q2 2025 and -$0.15 in Q1 2025.